Understanding the
21st Century Cures Act: Information Blocking and Implications for
Non-Compliance

#Watch | #Learn | #Improve

Join us for an insightful exploration into the 21st Century Cures Act, a legislation reshaping healthcare and the way we manage patient data in the United States. Dive deep into the realm of information blocking, understanding its nuances, goals, and the consequences organizations could face for non-compliance.
Empty space, drag to resize

 Duration: 20 min.

Who should attend?

Healthcare providers

Policy makers and health regulation enthusiasts

Policy makers and health regulation enthusiasts

Health Information Exchange (HIE) organizations

Medical researchers and innovators

Patients and patient advocacy groups

interested in understanding their rights to health data access

Key takeaways

01

Introduction to the 21st Century Cures Act

Learn the origins and motivations behind this landmark legislation and its mission to foster innovation and advance medical research.

02

Demystifying Information Blocking

Understand what constitutes information blocking and its implications in the contemporary healthcare scenario.

03

Goals of Addressing Information Blocking

Delve into the intended benefits, such as improved patient access to health information, promoting data transparency, and fostering an interoperable healthcare system

04

Consequences of Non-Compliance

Gain insights into the penalties, both financial and reputational, that can be imposed on entities found to be information blocking.

Meet the speakers

Alexander S., MD

Co-founder, CMIO
Graduate of the Harvard School.
Renowned clinical cardiologist with over 30 years experience in population- and value-based practice and development of effective strategies for patient and proxy education and engagement in long-term therapeutic partnerships.

Joshua D., Esq.

General Counsel
With a strong background in pharma and biotech patent litigation and technology contracting, Joshua has considerable experience in advising life sciences companies in the protection of their competitive assets.